Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.76 |
| ▸ | MEN1 | O00255 | 6/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.76 |
| ▸ | GAA | P10253 | 6/20 | 0.70 |
| ▸ | RAB9A | P51151 | 4/20 | 0.70 |
| ▸ | NPC1 | O15118 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | MAOA | P21397 | 4/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | MGAM | O43451 | 1/20 | 0.64 |
| ▸ | SI | P14410 | 1/20 | 0.64 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.64 |
| ▸ | GUSB | P08236 | 1/20 | 0.63 |
| ▸ | MAOB | P27338 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18980780 | 1.00 | MAPT (0.76) | MAPTMEN1KMT2AMAPK1GAA | |
| SCHEMBL17150984 | 1.00 | MAPT (0.76) | MAPTMEN1KMT2AMAPK1GAA | |
| SCHEMBL13186607 | 0.90 | MAPT (0.84) | MAPTMEN1KMT2AMAPK1GAA | |
| SCHEMBL1436233 | 0.85 | MAPT (0.79) | MAPTMEN1KMT2AMAPK1GAA | |
| SCHEMBL1436231 | 0.85 | MAPT (0.79) | MAPTMEN1KMT2AMAPK1GAA | |
| SCHEMBL8265955 | 0.84 | MAPT (0.66) | MAPTMEN1KMT2AMAPK1GAA | |
| SCHEMBL24625815 | 0.83 | MAOA (0.84) | MAPTMEN1KMT2AGAARAB9A | |
| SCHEMBL16742020 | 0.83 | GUSB (0.64) | MAPTMEN1KMT2AMAPK1GAA | |
| SCHEMBL16742019 | 0.83 | GUSB (0.64) | MAPTMEN1KMT2AMAPK1GAA | |
| SCHEMBL23831837 | 0.82 | MAOA (0.61) | MAPTMEN1KMT2AMAPK1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9809562-B2 | NAT10 modulators for treating or preventing laminopathies, aging and cancer | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2017-11-07 | — | — | US | disclosed |
| US-20170174644-A1 | NAT10 MODULATORS FOR TREATING OR PREVENTING LAMINOPATHIES, AGING AND CANCER | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174644-A1 | NAT10 MODULATORS FOR TREATING OR PREVENTING LAMINOPATHIES, AGING AND CANCER | LMNB2, LMNB1, LMNA | MAPT 563/4885MEN1 824/4885KMT2A 2087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.